Loading interactive chart...
1DInterval:
Date Range
1 min
Advertisement
U.S. markets closed
S&P Futures
5,075.75 -31.75 (-0.62%) Dow Futures
38,604.00 -76.00 (-0.20%) Nasdaq Futures
17,465.00 -199.50 (-1.13%) Russell 2000 Futures
2,010.10 +3.30 (+0.16%) Crude Oil
82.62 -0.19 (-0.23%) Gold
2,330.70 -7.70 (-0.33%)
Alnylam Pharmaceuticals Inc (DUL.MU)
Munich - Munich Delayed Price. Currency in EUR
Follow
At close: 08:00AM CEST
Mountain
Settings
- Business Wire
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
CAMBRIDGE, Mass., April 18, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2024 on Thursday, May 2, 2024, before the U.S. financial markets open.
- Zacks
Why Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick
Alnylam Pharmaceuticals (ALNY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- Business Wire
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
CAMBRIDGE, Mass., April 07, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive results from the KARDIA-2 Phase 2 study evaluating the efficacy and safety of a single subcutaneous dose of zilebesiran when added to one of three standard of care antihypertensives including a thiazide-like diuretic (indapamide), calcium channel blocker (amlodipine) or angiotensin receptor blocker (olmesartan). Zilebesiran is an investigational RNAi the
Advertisement
Advertisement
Advertisement